The Lancet· 2020
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
- 5,017citations
- 2020year
Short summary
The ChAdOx1 nCoV-19 vaccine showed 62.1% efficacy with two standard doses and 90.0% efficacy with a low-then-standard dose regimen against symptomatic COVID-19 in an interim analysis of four trials.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Infectious Diseases
Infectious DiseasesMedicine